Core Viewpoint - Merit Medical Systems, Inc. has announced an asset purchase agreement with EndoGastric Solutions, Inc. for approximately $105 million, acquiring the EsophyX® Z+ device, which offers a minimally invasive treatment for GERD patients [1][3][26]. Financial Impact - The acquired assets from EndoGastric Solutions generated about $26 million in revenue for the twelve months ending December 31, 2023, and are expected to contribute between $13 million and $15 million in revenue from the closing date through December 31, 2024 [3][6]. - The acquisition is projected to add approximately $30 million in annualized revenue in the gastrointestinal endoscopy market, leveraging Merit's existing commercial footprint [6][26]. - Merit has updated its full-year 2024 financial guidance to reflect the impacts of this acquisition, reaffirming prior guidance for the standalone business [9][35]. Updated Financial Guidance - The updated financial guidance for the year ending December 31, 2024, includes net sales projected between $1.324 billion and $1.340 billion, reflecting a year-over-year growth of 5% to 7% [29]. - The cardiovascular segment is expected to generate net sales of $1.272 billion to $1.285 billion, while the endoscopy segment is projected to reach $53.3 million to $55.7 million, representing a significant increase from previous guidance [29]. - Non-GAAP earnings per share are now expected to be between $3.22 and $3.31, indicating a year-over-year increase of 7% to 10% [29]. Strategic Rationale - The acquisition aligns with Merit's Continued Growth Initiatives, enhancing its product portfolio in existing clinical specialties and expanding its presence in the multi-billion-dollar gastrointestinal market [26][7]. - The EsophyX Z+ device is designed to provide a durable, minimally invasive treatment option for chronic GERD, addressing a significant healthcare need [1][17].

GERD is a digestive disorder that occurs when the lower esophageal sphincter doesn't tighten correctly, allowing acid from the stomach to enter the esophagus. When this occurs chronically, it can result in serious health conditions, such as esophageal damage and cancer. The EsophyX Z+ device treats GERD by restoring the body's reflux barrier. * Non-GAAP net income; non-GAAP earnings per share; non-GAAP gross margin; non-GAAP operating margin and constant currency revenue are non-GAAP financial measures. A d ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Zacks Premium also includes the Zacks Style Scores. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. The Style Scores are broken down into four categories: Value investors love finding good ...

More on the News The FDA stumbled upon Jiangsu Shenli when looking into the possibility of China-made plastic syringes leaking, shattering, or having other quality issues. The officials accused Jiangsu Shenli of marketing 29 different sizes and configurations of piston syringes without clearance or approval. Merit Medical is taking action to shift from Jiangsu Shenli syringes immediately. In the interim, to avoid product shortages, the company is likely to ship products containing the Jiangsu Shenli syringe ...

SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at merit.com. Contacts: To acc ...

SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. Merit will hold its investor conference call on the same day (Thursday, August 1, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access t ...

"Hurry up and wait" remains the order of the day for Merit Medical (NASDAQ:MMSI) and its shareholders. While the company has executed pretty well since my last update (some revenue and EBITDA outperformance), and the shares are up about 20%, I suspect there may be some investor frustration that there hasn't been more news to drive a fundamental shift in investment theses – the company has been reasonable (if not conservative) with guidance, hasn't done any big M&A, and has just stuck to its knitting. I rema ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Zacks Premium includes access to the Zacks Style Scores as well. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating ...

A month has gone by since the last earnings report for Merit Medical (MMSI) . Shares have added about 5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Merit Medical due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Merit Medical Q1 Earnings Top Estimates, Margins U ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...